Bruker's new solariX mass spectrometer gives ten-fold increase in
sensitivity
5 June 2009
Bruker Daltonics has launched the solariX, its next generation hybrid
Qq-FTMS platform. The solariX is the culmination of a number of key
technology developments that deliver unique capabilities and
unparalleled ultra-high resolution mass spectrometry performance and
versatility.
At the core of these innovations are dramatically improved broad-band
mass resolving power (8x over earlier platforms), sensitivity (> 10x
over earlier platforms) and dynamic range. These dramatic improvements
help address today’s most challenging top-down proteomics and complex
mixture applications.
Its broad-band, ultra-high resolving power (> 1,000,000 @ m/z 400,
for a 7 tesla instrument) and outstanding sub-ppm mass accuracy make the
solariX more powerful than any previous mass spectrometer for the
analysis of extremely complex mixtures.
This extraordinary increase in the number of available m/z channels
is essential for tackling very complex mixtures, especially those that
are not amenable to high-resolution chromatography separation
techniques.
These applications can include: hydrocarbon related analysis (petroleomics),
environmental soil/sediment analysis, small-molecule biological tissue
MALDI imaging, metabolomics, and the inherently complex peak patterns
resulting from top-down proteomics.
For applications that require high performance LC-FTMS or LC-MS/FTMS,
the solariX offers faster and smart data-dependent acquisition
capabilities. Moreover, sub-ppm mass accuracy is maintained throughout
the LC-MS analysis using Bruker’s proprietary Ion Charge Control (ICC™)
method.
Adding to the existing arsenal of top-down proteomics structural
fragmentation tools (ECD, Q-CID, in-cell SORI-CID), solariX is now the
first FTMS system with Electron Transfer Dissociation (ETD).
This exciting new technique is superb for in-depth, comprehensive
analysis of proteins and peptides and their labile, post-translational
modifications (PTMs). ETD-analysis has been fully automated and can be
combined with LC-MS/FTMS workflows in combination with quadrupole
fragmentation (Q-CID) to provide unprecedented levels of protein
structural information.
The solariX can also be easily incorporated into the workflows of
other mainstream proteomics platforms such as the new Bruker
ultrafleXtreme MALDI-TOF/TOF (for high throughput biomarker discovery/quantitation
and Edmass™ protein sequencing) and amaZon ion trap (for high-throughput
LC-MS/MS).
The solariX provides complementary analytical capabilities through
the combination of unique dissociation tools with the performance
necessary to address the most challenging structural or functional
proteomics applications, including protein structural studies and PTM
characterization.
The new dual ion funnel source combined with a unique rf ion transfer
system makes the solariX FTMS as intuitive and easy to use as a benchtop
ion trap mass spectrometer. Operation of the instrument is performed
using Bruker’s unified Compass software, enabling researchers to harness
the analytical power and versatility of FTMS with ease.
The solariX can be configured with a unique dual ESI/MALDI source,
and a range of API source options (APCI, GC-APCI, APPI). Low
maintenance, refrigerated magnets are standard at several magnetic field
options, including 7T, 9.4T, 12T and 15T. The solariX is the realization
of the highest performance FTMS product ever released to the
marketplace, equally well suited for small molecule or protein
applications.
Professor André Deelder of Leiden University Medical Center,
Netherlands, commented: “Part of our mission is to leverage new,
enabling technologies for life science research. Therefore, we are very
excited to have received the first two solariX systems, which are 12
tesla and 15 tesla instruments. The advanced performance and added
capabilities of solariX have been integrated into our proteomics and
metabolomics workflows. They will increase our capacity for in-depth
characterization and quantitative analysis of the large number of
samples generally encountered in clinical studies, and will enable us to
identify more proteins with very high quantitative precision.”
Professor Michael Gross of Washington University, St. Louis, MO,
stated: “Our work in top-down protein characterization will greatly
benefit from the enhanced sensitivity and ETD capabilities of the
solariX FTMS. We have purchased the solariX 12T system and are very much
looking forward to having it in our laboratory.”
Bookmark this page